Central Nervous System Therapeutics Market By Drug Class (Anesthetics, Anticonvulsants, Antiemetics, CNS Stimulants, Pain Relievers, Antidepressant, Antipsychotics, Others), By Disease Type (Neurovascular Diseases, CNS Trauma, Neurodegenerative Disorders {Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Amyotrophic Lateral Sclerosis, Other}, Mental Health {Anxiety Disorders, Epilepsy, Mood Disorders, Psychotic Disorders, Others}, Infectious Diseases, CNS Cancer, Others), By Route of Administration (Oral, Intravenous, Transdermal, Inhalational), By End-User (Hospitals and Clinics, Home Healthcare, Rehabilitation Center, Research Institutes), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & forecast parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Central Nervous System Therapeutics Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. The Growing prevalence of neurological disorders worldwide drives demand for treatments

3.2.2. Advancements in drug development and innovative CNS therapeutic approaches rising

3.2.3. Increasing investment in R&D for neurodegenerative and psychiatric disorder solutions

3.3. Key industry pitfalls & challenges

3.3.1. High cost of CNS therapies and limited reimbursement policies hinder accessibility

3.3.2. Complex clinical trials and stringent regulatory approvals delay market expansion

3.3.3. Lack of awareness and diagnosis in emerging economies restricts treatment adoption

3.4. Market Opportunities

3.4.1. Emerging markets show significant growth potential due to healthcare improvements

3.4.2. Expanding adoption of biologics and gene therapies in CNS disorder treatment

3.4.3. Advancements in precision medicine and digital technologies create new possibilities

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Central Nervous System Therapeutics Market, Drug Class Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Drug Class, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Anesthetics

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Anticonvulsants

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4. Antiemetics

4.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.5. CNS Stimulants

4.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.6. Pain Relievers

4.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.7. Antidepressant

4.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.8. Antipsychotics

4.8.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.9. Others

4.9.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Central Nervous System Therapeutics Market, Disease Type Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Disease Type, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Neurovascular Diseases

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. CNS Trauma

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Neurodegenerative Disorders

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4.2. Alzheimer’s Disease

5.4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4.3. Parkinson’s Disease

5.4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4.4. Huntington’s Disease

5.4.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4.5. Amyotrophic Lateral Sclerosis

5.4.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4.6. Other

5.4.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5. Mental Health

5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5.2. Anxiety Disorders

5.5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5.3. Epilepsy

5.5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5.4. Mood Disorders

5.5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5.5. Psychotic Disorders

5.5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5.6. Others

5.5.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.6. Infectious Diseases

5.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.7. CNS Cancer

5.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.8. Others

5.8.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Central Nervous System Therapeutics Market, Route of Administration Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Route of Administration, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Oral

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Intravenous

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Transdermal

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.5. Inhalational

6.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Central Nervous System Therapeutics Market, End-User Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By End-User, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Hospitals and Clinics

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Home Healthcare

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.4. Rehabilitation Center

7.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.5. Research Institutes

7.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Central Nervous System Therapeutics Market, Region Segment Analysis

8.1. Overview

8.1.1. Global Market Revenue Share, By Region, 2025 & 2035

8.1.2. Global Market Revenue, By Region, 2025-2035(USD Billion)

8.2. North America

8.2.1. North America Market Revenue, By Country, 2025-2035(USD Billion)

8.2.2. North America Market Revenue, By Drug Class, 2025-2035

8.2.3. North America Market Revenue, By Disease Type, 2025-2035

8.2.4. North America Market Revenue, By Route of Administration, 2025-2035

8.2.5. North America Market Revenue, By End-User, 2025-2035

8.2.6. The U.S.

8.2.6.1. U.S. Market Revenue, By Drug Class, 2025-2035

8.2.6.2. U.S. Market Revenue, By Disease Type, 2025-2035

8.2.6.3. U.S. Market Revenue, By Route of Administration, 2025-2035

8.2.6.4. U.S. Market Revenue, By End-User, 2025-2035

8.2.7. Canada

8.2.7.1. Canada Market Revenue, By Drug Class, 2025-2035

8.2.7.2. Canada Market Revenue, By Disease Type, 2025-2035

8.2.7.3. Canada Market Revenue, By Route of Administration, 2025-2035

8.2.7.4. Canada Market Revenue, By End-User, 2025-2035

8.3. Europe

8.3.1. Europe Market Revenue, By Country, 2025-2035(USD Billion)

8.3.2. Europe Market Revenue, By Drug Class, 2025-2035

8.3.3. Europe Market Revenue, By Disease Type, 2025-2035

8.3.4. Europe Market Revenue, By Route of Administration, 2025-2035

8.3.5. Europe Market Revenue, By End-User, 2025-2035

8.3.6. Germany

8.3.6.1. Germany Market Revenue, By Drug Class, 2025-2035

8.3.6.2. Germany Market Revenue, By Disease Type, 2025-2035

8.3.6.3. Germany Market Revenue, By Route of Administration, 2025-2035

8.3.6.4. Germany Market Revenue, By End-User, 2025-2035

8.3.7. France

8.3.7.1. France Market Revenue, By Drug Class, 2025-2035

8.3.7.2. France Market Revenue, By Disease Type, 2025-2035

8.3.7.3. France Market Revenue, By Route of Administration, 2025-2035

8.3.7.4. France Market Revenue, By End-User, 2025-2035

8.3.8. U.K.

8.3.8.1. U.K. Market Revenue, By Drug Class, 2025-2035

8.3.8.2. U.K. Market Revenue, By Disease Type, 2025-2035

8.3.8.3. U.K. Market Revenue, By Route of Administration, 2025-2035

8.3.8.4. U.K. Market Revenue, By End-User, 2025-2035

8.3.9. Italy

8.3.9.1. Italy Market Revenue, By Drug Class, 2025-2035

8.3.9.2. Italy Market Revenue, By Disease Type, 2025-2035

8.3.9.3. Italy Market Revenue, By Route of Administration, 2025-2035

8.3.9.4. Italy Market Revenue, By End-User, 2025-2035

8.3.10. Spain

8.3.10.1. Spain Market Revenue, By Drug Class, 2025-2035

8.3.10.2. Spain Market Revenue, By Disease Type, 2025-2035

8.3.10.3. Spain Market Revenue, By Route of Administration, 2025-2035

8.3.10.4. Spain Market Revenue, By End-User, 2025-2035

8.3.11. Rest of Europe

8.3.11.1. Rest of Europe Market Revenue, By Drug Class, 2025-2035

8.3.11.2. Rest of Europe Market Revenue, By Disease Type, 2025-2035

8.3.11.3. Rest of Europe Market Revenue, By Route of Administration, 2025-2035

8.3.11.4. Rest of Europe Market Revenue, By End-User, 2025-2035

8.4. Asia Pacific

8.4.1. Asia Pacific Market Revenue, By Country, 2025-2035(USD Billion)

8.4.2. Asia Pacific Market Revenue, By Drug Class, 2025-2035

8.4.3. Asia Pacific Market Revenue, By Disease Type, 2025-2035

8.4.4. Asia Pacific Market Revenue, By Route of Administration, 2025-2035

8.4.5. Asia Pacific Market Revenue, By End-User, 2025-2035

8.4.6. China

8.4.6.1. China Market Revenue, By Drug Class, 2025-2035

8.4.6.2. China Market Revenue, By Disease Type, 2025-2035

8.4.6.3. China Market Revenue, By Route of Administration, 2025-2035

8.4.6.4. China Market Revenue, By End-User, 2025-2035

8.4.7. Japan

8.4.7.1. Japan Market Revenue, By Drug Class, 2025-2035

8.4.7.2. Japan Market Revenue, By Disease Type, 2025-2035

8.4.7.3. Japan Market Revenue, By Route of Administration, 2025-2035

8.4.7.4. Japan Market Revenue, By End-User, 2025-2035

8.4.8. India

8.4.8.1. India Market Revenue, By Drug Class, 2025-2035

8.4.8.2. India Market Revenue, By Disease Type, 2025-2035

8.4.8.3. India Market Revenue, By Route of Administration, 2025-2035

8.4.8.4. India Market Revenue, By End-User, 2025-2035

8.4.9. Australia

8.4.9.1. Australia Market Revenue, By Drug Class, 2025-2035

8.4.9.2. Australia Market Revenue, By Disease Type, 2025-2035

8.4.9.3. Australia Market Revenue, By Route of Administration, 2025-2035

8.4.9.4. Australia Market Revenue, By End-User, 2025-2035

8.4.10. South Korea

8.4.10.1. South Korea Market Revenue, By Drug Class, 2025-2035

8.4.10.2. South Korea Market Revenue, By Disease Type, 2025-2035

8.4.10.3. South Korea Market Revenue, By Route of Administration, 2025-2035

8.4.10.4. South Korea Market Revenue, By End-User, 2025-2035

8.4.11. Singapore

8.4.11.1. Singapore Market Revenue, By Drug Class, 2025-2035

8.4.11.2. Singapore Market Revenue, By Disease Type, 2025-2035

8.4.11.3. Singapore Market Revenue, By Route of Administration, 2025-2035

8.4.11.4. Singapore Market Revenue, By End-User, 2025-2035

8.4.12. Rest of Asia Pacific

8.4.12.1. Rest of Asia Pacific Market Revenue, By Drug Class, 2025-2035

8.4.12.2. Rest of Asia Pacific Market Revenue, By Disease Type, 2025-2035

8.4.12.3. Rest of Asia Pacific Market Revenue, By Route of Administration, 2025-2035

8.4.12.4. Rest of Asia Pacific Market Revenue, By End-User, 2025-2035

8.5. Latin America

8.5.1. Latin America Market Revenue, By Country, 2025-2035(USD Billion)

8.5.2. Latin America Market Revenue, By Drug Class, 2025-2035

8.5.3. Latin America Market Revenue, By Disease Type, 2025-2035

8.5.4. Latin America Market Revenue, By Route of Administration, 2025-2035

8.5.5. Latin America Market Revenue, By End-User, 2025-2035

8.5.6. Brazil

8.5.6.1. Brazil Market Revenue, By Drug Class, 2025-2035

8.5.6.2. Brazil Market Revenue, By Disease Type, 2025-2035

8.5.6.3. Brazil Market Revenue, By Route of Administration, 2025-2035

8.5.6.4. Brazil Market Revenue, By End-User, 2025-2035

8.5.7. Argentina

8.5.7.1. Argentina Market Revenue, By Drug Class, 2025-2035

8.5.7.2. Argentina Market Revenue, By Disease Type, 2025-2035

8.5.7.3. Argentina Market Revenue, By Route of Administration, 2025-2035

8.5.7.4. Argentina Market Revenue, By End-User, 2025-2035

8.5.8. Mexico

8.5.8.1. Mexico Market Revenue, By Drug Class, 2025-2035

8.5.8.2. Mexico Market Revenue, By Disease Type, 2025-2035

8.5.8.3. Mexico Market Revenue, By Route of Administration, 2025-2035

8.5.8.4. Mexico Market Revenue, By End-User, 2025-2035

8.5.9. Rest of Latin America

8.5.9.1. Rest of Latin America Market Revenue, By Drug Class, 2025-2035

8.5.9.2. Rest of Latin America Market Revenue, By Disease Type, 2025-2035

8.5.9.3. Rest of Latin America Market Revenue, By Route of Administration, 2025-2035

8.5.9.4. Rest of Latin America Market Revenue, By End-User, 2025-2035

8.6. MEA

8.6.1. MEA Market Revenue, By Country, 2025-2035(USD Billion)

8.6.2. MEA Market Revenue, By Drug Class, 2025-2035

8.6.3. MEA Market Revenue, By Disease Type, 2025-2035

8.6.4. MEA Market Revenue, By Route of Administration, 2025-2035

8.6.5. MEA Market Revenue, By End-User, 2025-2035

8.6.6. GCC Countries

8.6.6.1. GCC Countries Market Revenue, By Drug Class, 2025-2035

8.6.6.2. GCC Countries Market Revenue, By Disease Type, 2025-2035

8.6.6.3. GCC Countries Market Revenue, By Route of Administration, 2025-2035

8.6.6.4. GCC Countries Market Revenue, By End-User, 2025-2035

8.6.7. South Africa

8.6.7.1. South Africa Market Revenue, By Drug Class, 2025-2035

8.6.7.2. South Africa Market Revenue, By Disease Type, 2025-2035

8.6.7.3. South Africa Market Revenue, By Route of Administration, 2025-2035

8.6.7.4. South Africa Market Revenue, By End-User, 2025-2035

8.6.8. Rest of Middle-East & Africa

8.6.8.1. Rest of Middle-East & Africa Market Revenue, By Drug Class, 2025-2035

8.6.8.2. Rest of Middle-East & Africa Market Revenue, By Disease Type, 2025-2035

8.6.8.3. Rest of Middle-East & Africa Market Revenue, By Route of Administration, 2025-2035

8.6.8.4. Rest of Middle-East & Africa Market Revenue, By End-User, 2025-2035

9. Company Profile

9.1. Biogen Inc.

9.1.1. Business Overview

9.1.2. Financial Performance

9.1.3. Product/Service Offerings

9.1.4. Strategies & recent developments

9.1.5. SWOT Analysis

9.2. Eli Lilly and Company

9.2.1. Business Overview

9.2.2. Financial Performance

9.2.3. Product/Service Offerings

9.2.4. Strategies & recent developments

9.2.5. SWOT Analysis

9.3. Pfizer Inc.

9.3.1. Business Overview

9.3.2. Financial Performance

9.3.3. Product/Service Offerings

9.3.4. Strategies & recent developments

9.3.5. SWOT Analysis

9.4. Novartis AG

9.4.1. Business Overview

9.4.2. Financial Performance

9.4.3. Product/Service Offerings

9.4.4. Strategies & recent developments

9.4.5. SWOT Analysis

9.5. Johnson & Johnson

9.5.1. Business Overview

9.5.2. Financial Performance

9.5.3. Product/Service Offerings

9.5.4. Strategies & recent developments

9.5.5. SWOT Analysis

9.6. F. Hoffmann-La Roche Ltd.

9.6.1. Business Overview

9.6.2. Financial Performance

9.6.3. Product/Service Offerings

9.6.4. Strategies & recent developments

9.6.5. SWOT Analysis

9.7. Bristol-Myers Squibb Company

9.7.1. Business Overview

9.7.2. Financial Performance

9.7.3. Product/Service Offerings

9.7.4. Strategies & recent developments

9.7.5. SWOT Analysis

9.8. Merck & Co., Inc.

9.8.1. Business Overview

9.8.2. Financial Performance

9.8.3. Product/Service Offerings

9.8.4. Strategies & recent developments

9.8.5. SWOT Analysis

9.9. AstraZeneca PLC

9.9.1. Business Overview

9.9.2. Financial Performance

9.9.3. Product/Service Offerings

9.9.4. Strategies & recent developments

9.9.5. SWOT Analysis

9.10. AbbVie Inc.

9.10.1. Business Overview

9.10.2. Financial Performance

9.10.3. Product/Service Offerings

9.10.4. Strategies & recent developments

9.10.5. SWOT Analysis

9.11. Sanofi S.A.

9.11.1. Business Overview

9.11.2. Financial Performance

9.11.3. Product/Service Offerings

9.11.4. Strategies & recent developments

9.11.5. SWOT Analysis

9.12. Takeda Pharmaceutical Company Limited

9.12.1. Business Overview

9.12.2. Financial Performance

9.12.3. Product/Service Offerings

9.12.4. Strategies & recent developments

9.12.5. SWOT Analysis

9.13. Amgen Inc.

9.13.1. Business Overview

9.13.2. Financial Performance

9.13.3. Product/Service Offerings

9.13.4. Strategies & recent developments

9.13.5. SWOT Analysis

9.14. Otsuka Pharmaceutical Co., Ltd.

9.14.1. Business Overview

9.14.2. Financial Performance

9.14.3. Product/Service Offerings

9.14.4. Strategies & recent developments

9.14.5. SWOT Analysis

9.15. Teva Pharmaceutical Industries Ltd.

9.15.1. Business Overview

9.15.2. Financial Performance

9.15.3. Product/Service Offerings

9.15.4. Strategies & recent developments

9.15.5. SWOT Analysis

9.16. UCB S.A.

9.16.1. Business Overview

9.16.2. Financial Performance

9.16.3. Product/Service Offerings

9.16.4. Strategies & recent developments

9.16.5. SWOT Analysis

9.17. Alkermes plc

9.17.1. Business Overview

9.17.2. Financial Performance

9.17.3. Product/Service Offerings

9.17.4. Strategies & recent developments

9.17.5. SWOT Analysis

9.18. H. Lundbeck A/S

9.18.1. Business Overview

9.18.2. Financial Performance

9.18.3. Product/Service Offerings

9.18.4. Strategies & recent developments

9.18.5. SWOT Analysis

9.19. GlaxoSmithKline plc (GSK)

9.19.1. Business Overview

9.19.2. Financial Performance

9.19.3. Product/Service Offerings

9.19.4. Strategies & recent developments

9.19.5. SWOT Analysis